<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140137</url>
  </required_header>
  <id_info>
    <org_study_id>CHECKAUTO</org_study_id>
    <nct_id>NCT03140137</nct_id>
  </id_info>
  <brief_title>Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases</brief_title>
  <official_title>Retrospective Observational Study on the Safety of Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma and Lung Cancers in Patients With Pre-Existing Autoimmune Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing
      autoimmune conditions. This retrospective nation-wide study will assess their tolerance in
      patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors
      for an advanced cancer in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">January 23, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Autoimmune disease flare</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Increase in the activity of the pre-existing autoimmune disease as assessed by the treating physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other immune/inflammatory complications</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Development of a new immune/inflammatory condition after the start of the therapy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Advanced Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Checkpoint inhibitor therapy</intervention_name>
    <description>Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a pre-existing autoimmune disease who received immune checkpoint inhibitors
        for the treatment of an advanced cancer in clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-existing autoimmune disease as diagnosed by the physician

          -  Immune checkpoint inhibitor therapy for an advanced cancer

        Exclusion Criteria:

          -  Auto-immune disease developed only after the start of the immune checkpoint inhibitor
             therapy

          -  Absence of follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Divi CORNEC</last_name>
    <role>Study Director</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Divi CORNEC</last_name>
    <phone>+33298347264</phone>
    <email>divi.cornec@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH d'AIX</name>
      <address>
        <city>AIX en PROVENCE</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARTINEZ Stéphanie</last_name>
      <email>smartinez@ch-aix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BONNIAUD Bertille</last_name>
      <email>bertille.bonniaud@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BIZIEUX Acya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie BENETON</last_name>
      <email>nbeneton@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de MACON</name>
      <address>
        <city>Macon</city>
        <zip>78018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GONZALEZ</last_name>
      <email>gigonzalez@ch-macon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

